ARTICLE | Company News
Althea, Lorantis deal
May 2, 2005 7:00 AM UTC
Althea will manufacture the protein component of Lorantis' HepVax vaccine, which is in preclinical development to treat HBV. HepVax consists of the HBV core antigen and the RC-529 adjuvant from Corix...